CUVITRU is a ready-to-use liquid medicine that is given under the skin (subcutaneously) to treat primary immunodeficiency (PI) in people 2 years and older.
*CUVITRU was studied in 77 people with primary immunodeficiency (PI) ≥2 years of age. The average infusion time was 0.95 hours (range, 0.2-6.4 hours).
†You’ll infuse your first 2 infusions at 10 to 20 mL/hour/site. After that, you’ll be able to increase your rate, as tolerated.
‡ CUVITRU can be infused at the fastest rates of any subQ (up to 60 mL/hour/site as tolerated). You’ll infuse your first 2 infusions at 10 to 20 mL/hour/site. After that, you'll be able to increase your rate to 60 mL/hr/site, as tolerated. Infuse at up to 4 sites simultaneously.
Patients reported convenience as2:
They reported treatment interference as2:
Quality of life was measured in other areas and did not show a significant improvement for patients: TSQM-9, no significant improvement in how satisfied patients were with their treatment or how effective they felt it was; LQI, no significant change reported in problems related to therapy or the therapy setting. In other assessments, health-related quality of life differences between IVIG and subQ IG treatment were not statistically significant.
IVIG=intravenous immunoglobulin; LQI=Life Quality Index; TSQM=Treatment Satisfaction Questionnaire for Medication.
*These results came from the LQI and TSQM-9. Both TSQM-9 and LQI were measured in patients aged 2 to 12 (with a parent observer) and in patients aged ≥13 (with the patient as the observer). TSQM-9, P<0.001; LQI, P=0.008.
1. CUVITRU. Prescribing Information, Takeda Pharmaceuticals USA Inc.; 2023.
2. Meckley LM, Wu Y, Ito D, et al. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary Immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials. BMC Immunol. 2020;21(1):24. doi:10.1186/s12865-020-00346-z